A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Scott M. Hammer, Kathleen Squires, Michael D. Hughes, Janet M. Grimes, Lisa M. Demeter, Judith S. Currier, Joseph J. Eron, Judith Feinberg, Henry H. Balfour, Lawrence Deyton, Jeffrey Chodakewitz, Margaret A. Fischl, John Phair, Louise Pedneault, Bach‐Yen Nguyen
New England Journal of Medicine · 1997 · 2,688 citationsOpen access
Abstract
BACKGROUND: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. METHODS: A total of 1156 patients not previously treated with lamivudine or protease inhibitors were stratified according to CD4 cell count (50 or fewer vs. 51 to 200 cells per cubic millimeter) and randomly assigned to one of two daily regimens: 600 mg of zidovudine (or stavudine) and 300 mg of lamivudine, or that regimen with 2400 mg of indinavir. The primary end point was the time to the development of the acquired immunodeficiency syndrome (AIDS) or death. RESULTS: The proportion of patients whose disease progressed to AIDS or death was lower with indinavir, zidovudine, and lamivudine (6 percent) than with zidovudine and lamivudine alone (11 percent; estimated hazard ratio, 0.50; 95 percent confidence interval, 0.33 to 0.76; P=0.001). Mortality in the two groups was 1.4 percent and 3.1 percent, respectively (estimated hazard ratio, 0.43; 95 percent confidence interval, 0.19 to 0.99; P=0.04). The effects of treatment were similar in both CD4 cell strata. The responses of CD4 cells and plasma HIV-1 RNA paralleled the clinical results. CONCLUSIONS: Treatment with indinavir, zidovudine, and lamivudine as compared with zidovudine and lamivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidovudine.
Cite this paper
Hammer, S. M., Squires, K., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J., Balfour, H. H., Deyton, L., Chodakewitz, J., Fischl, M. A., Phair, J., Pedneault, L., Nguyen, B., & Cook, J. C. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine, 337(11), 725–733. https://doi.org/10.1056/nejm199709113371101
Read it with every claim anchored
Add this paper to a project, ask questions of it, and get answers that point to the exact passage.
Start freeRelated papers
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility2009
- Prevention of HIV-1 Infection with Early Antiretroviral Therapy2011
- 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults1993
- HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor1996
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment1994
Metadata from OpenAlex (CC0). Citations are generated from the published record.